Worldwide Clinical Trials

JUNE 15, 2022

Further, some patients are still hesitant to go into the clinic, and the prevalence of misinformation from the pandemic has led to greater concerns about therapies like gene therapies and the impact they fear it will have on their RNA/DNA. Working with a centralized IBC/IRB provider can speed up your process. .

Gene Therapy 130

Gene Therapy Gene Clinical Trials Clinical Trials 130

pharmaphorum

JANUARY 10, 2023

Since then, the two partners have developed multiple AI-based applications including a platform for selecting neoantigens for use in individualised cancer vaccines and an early warning system for high risk SARS-CoV-2 variants based on how well they can evade the immune system and their transmissibility.

Vaccination 116

Vaccination Vaccine Clinical Trials Clinical Trials 116

XTalks

NOVEMBER 30, 2023

The safety and efficacy of Cabenuva were established through two randomized, open-label, controlled clinical trials involving 1,182 HIV-infected adults who were virologically suppressed (HIV-1 RNA less than 50 copies/mL) before initiating Cabenuva treatment. Additionally, Gag-specific CD8+ T cells demonstrated an increase of 1.7

FDA Approval 111

FDA Approval Gene Therapy Gene Clinical Trials 111

The Pharma Data

DECEMBER 23, 2020

Additionally, Phase 1 clinical data found INO-4800 to have a favorable safety and tolerability profile with no serious adverse events reported; only six Grade 1 adverse events (AEs) were observed, primarily minor injection site reactions. . ” Findings from the Phase 1 Clinical Trial.

DNA 40

DNA Vaccination Vaccine Immune Response 40

Pharmaceutical Technology

NOVEMBER 22, 2022

When an mRNA vaccine is administered, a patient’s body produces that protein to prompt a desired immune response. According to GlobalData, Moderna and BioNTech are currently leading the charge with the highest percentage of mRNA clinical trials, representing 7% and 5% of all mRNA studies, respectively.

Manufacturing 130

Manufacturing Vaccination Vaccine RNA 130

pharmaphorum

AUGUST 27, 2020

The common challenge is undertaking lengthy and capital-intensive phase II/III clinical trials. For example, if a company is carrying out clinical trials, then a clinical research organisation is needed to run them. Companies have struggled to access intermediate capital. If we get it right, the prize is great.

Vaccination 122

Vaccination Vaccine Life Science Clinical Trials 122

Find Me Cure

OCTOBER 13, 2019

There currently are drugs that do just that but now they’re in clinical trials for metastatic breast cancer as well. An enzyme involved in DNA repair can be the key to making chemotherapy more effective. PARP inhibitors work by blocking the function of the PARP enzyme, thus preventing the repair of the tumour DNA.

Development 52

Development DNA Clinical Trials Clinical Trials 52

pharmaphorum

OCTOBER 12, 2022

The payload, Del Bourgo tell us, is the therapeutic DNA or RNA sequence that will cure or fix damaged cells. Similar to how we injected mRNA into people to trigger an immune response and train their immune system against COVID-19, genomic medicine repairs cellular or molecular mechanisms that are dysfunctional and cause disease.”.

Genome 105

Genome Genomics Medicine Development 105

pharmaphorum

FEBRUARY 22, 2021

Bluebird Bio’s decision to hit pause on the launch of Zynteglo for beta thalassaemia after two cases of cancer were seen in a clinical trial could see fears over the safety of viral vectors used to deliver gene therapies resurface. . million in Europe.

Gene Therapy 52

Gene Therapy Gene Gene Sequencing Gene Expression 52

The Pharma Data

JANUARY 13, 2021

13, 2021 — A single-shot COVID-19 vaccine from Johnson & Johnson has shown very strong results in early clinical trials, potentially providing a significant boost to U.S. The vaccine produced an immune response of all 805 clinical trial participants within two months of inoculation, according to results published Jan.

Vaccination 40

Vaccination Vaccine Trials Immune Response 40

Delveinsight

AUGUST 6, 2020

Zydus starts phase 2 COVID-19 vaccine trial after clearing safety test. Zydus Cadila has finished a phase 1 clinical trial of its COVID-19 vaccine ZyCoV-D, setting it up to move straight into a 1,000-subject phase 2 study. ZyCoV-D is designed to introduce DNA that encodes for a viral protein into human cells.

Allergies 53

Allergies Vaccination Vaccine Gene Therapy 53

The Pharma Data

MAY 15, 2023

Through the acquisition, Gilead gains rights to a portfolio of small molecule inhibitors targeting PARP1 for oncology and MK2 for inflammatory diseases that could enter clinical trials later this year. Executive Vice President, Research, Gilead Sciences. “The Executive Vice President, Research, Gilead Sciences.

DNA 40

DNA Immune Response Medicine Development 40

The Pharma Data

NOVEMBER 18, 2020

.” Ming-Tain Lai, PhD, Chief Scientific Officer at OBI Pharma stated, “In the trial, OBI-833 demonstrated a favorable safety profile and generated detectable anti-Globo H IgM/IgG responses. ” Presentation number: 397P / Poster: ID 680. Additional information can be found at www.obipharma.com.

Vaccination 52

Vaccination Vaccine Immune Response Trials 52

Roots Analysis

AUGUST 23, 2024

Unveiling The Potential of mRNA Technology mRNA is a single-stranded molecule that relays the genetic instructions needed to make proteins from DNA in the cell nucleus to ribosomes. In theory we could do this for any infectious disease where we know enough about what molecules provoke an effective immune response.

Protein 40

Protein Vaccination Vaccine Immune Response 40

Cloudbyz

JULY 31, 2024

Liquid biopsies, for example, allow non-invasive monitoring of cancer progression and response to treatment by analyzing circulating tumor DNA (ctDNA) in blood samples. Personalized Post-Treatment Plans: Post-market diagnostics enable the customization of post-treatment care plans based on individual patient responses.

Gene Therapy 52

Gene Therapy Gene Medicine In-Vitro 52

The Pharma Data

DECEMBER 27, 2020

Even with the holidays among us, there were a number of clinical trial announcements. Vir Biotechnology and GlaxoSmithKline dosed the first patient in a new sub-trial of a Phase III study of monoclonal antibody VIR-7831 for hospitalized adults with COVID-19. Here’s a look. COVID-19-Related.

Trials 52

Trials Antibody Gene Therapy Gene 52

The Pharma Data

JANUARY 20, 2021

Nasdaq: INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, including COVID-19, cancer and HPV-associated diseases, today announced the pricing of an underwritten public offering of 17,700,000 shares of its common stock at a public offering price of $8.50

DNA 40

DNA Containment Immune Response Sales 40

WCG Clinical

MAY 28, 2024

This proliferative capacity allows a rapid response to an incoming threat, such as a viral infection. T cells and B cells also express specialized antigen receptors that impart specificity to the immune response, directing immune attack against foreign “non-self” targets while sparing “self” targets expressed by healthy tissue.

In-Vivo 40

In-Vivo Clinical Trials Clinical Trials FDA Approval 40

Delveinsight

DECEMBER 13, 2020

Even though clinical trial results were promising, adverse events and serious complications were observed. Unlike a typical virus, hepatitis B’s cccDNA permanently integrates itself into a healthy cell’s DNA. HBV DNA can be integrated into the host genome. and ribavirin, were officially approved for HCV GT1 treatment.

Genotype 52

Genotype FDA Approval DNA Drugs 52

Roots Analysis

MAY 21, 2024

Several LNP-based therapies are currently being evaluated in the clinical trials; majority of these are conducted for treating breast cancer, ovarian cancer and lung cancer. In addition, these can be modified with ligands in order to improve the specificity and selectivity of the gene therapy and reduce off-target effects.

Drug Delivery 40

Drug Delivery Drugs Gene Therapy Bioavailability 40

Delveinsight

DECEMBER 3, 2020

AMD Patients often have low levels of CD59, which is a protein that protects the retina from damage caused by a vital part of the body’s natural immune response called complement. In the 97-subject clinical trial, children who got OV101 orally once a day for three months improved by 0.7

Gene Therapy 52

Gene Therapy Gene Antibody Research 52

The Pharma Data

APRIL 7, 2023

The safety and tolerability of these combinations are broadly consistent with that observed in prior clinical trials and the known profiles of the individual medicines. It will be important to understand the key secondary endpoints as well as data for relevant subgroups.”

Trials 40

Trials DNA Medicine Development 40

The Pharma Data

DECEMBER 20, 2020

Many companies appear to be getting their clinical trial news updated ahead of the holidays. CureVac announced it has enrolled the first volunteer in the pivotal Phase IIb/III trial of its own mRNA vaccine candidate, CVnCoV against COVID-19. The DSMB gave the company the go-ahead to continue the trial without changes.

Trials 52

Trials Gene Therapy Vaccination Vaccine 52

The Pharma Data

NOVEMBER 29, 2020

HB-101, a non-replicating arenavirus vaccine, is being investigated in a double-blind Phase 2 clinical trial (NCT03629080) to assess safety, immunogenicity and efficacy in individuals receiving a kidney transplant from a living donor. Both technologies enable repeat administration to augment and refresh immune responses.

Vaccination 40

Vaccination Vaccine Clinical Trials Clinical Trials 40

The Pharma Data

OCTOBER 14, 2020

(Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that the first participant was enrolled in the observational PRECISION study (TNX-C002), to examine the immune responses to COVID-19 in healthy volunteers who have recovered from COVID-19 or were asymptomatic.

Vaccination 40

Vaccination Vaccine Development Medicine 40

The Pharma Data

DECEMBER 27, 2020

This year has been difficult, but it has reinforced the importance of our mission: to treat and potentially even reverse the effects of serious diseases and conditions by advancing our novel cell therapy product candidates through clinical trials and into the hands of physicians.

Manufacturing 40

Manufacturing Production Development Clinical Trials 40

The Pharma Data

JUNE 30, 2021

Mismatch repair deficiency (dMMR) occurs when the proteins that repair mismatch errors in DNA replication are missing or non-functional, leading to microsatellite instability-high (MSI-H) tumors. By harnessing the body’s own immune system to fight cancer, Opdivo has become an important treatment option across multiple cancers.

Trials 52

Trials Genome Genomics Containment 52

The Pharma Data

AUGUST 3, 2021

The company announced positive top-line results from the SURPASS-4 Phase 3 clinical trial of tirzepatide in adults with type 2 diabetes, evaluating A1C and body weight reductions from baseline. The trial compared tirzepatide to insulin glargine in adults with type 2 diabetes and increased cardiovascular risk.

Antibody 52

Antibody Sales Development Production 52

pharmaphorum

JULY 26, 2022

At a basic level, the virus’s protein ‘coat’ and the enzymes it uses to gain control of the host cell’s DNA mutate frequently, making it difficult to target with therapeutics. The reason there has been, as yet, no effective cure for the condition is due to the complexity of the virus and the way in which it is activated within the body.

Gene Therapy 140

Gene Therapy Protein Vaccination Vaccine 140

XTalks

MAY 17, 2024

HIV Vaccine Clinical Trials on the Watch: Past and Present Several promising clinical trials with HIV vaccines have been underway. The vaccine used a ‘mosaic’ approach, designed to trigger immune responses against a wide variety of HIV strains globally.

Vaccination 52

Vaccination Vaccine Research Immune Response 52

XTalks

SEPTEMBER 14, 2020

By the end of August, the World Health Organization (WHO) counted 33 vaccine candidates in some stage of clinical trial evaluation. Novavax has also tested its recombinant SARS-CoV-2 nanoparticle adjuvanted vaccine in a Phase I/II trial. The price of that prize is incalculable.

Vaccination 92

Vaccination Vaccine Antibody Life Science 92